Evercore ISI upgraded Cardinal Health (CAH) to Outperform from In Line with a $140 price target The current pharma adjusted operating income guidance of 4-6% only implies about 4% AOI growth for the remainder of FY25, which the firm calls conservative as it sees upside to Cardinal’s long-term guidance, the analyst tells investors. FY25 EPS likely has upside with FY26 bringing a return to Cardinal’s 12%- 14% compound annual growth rate, the analyst added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAH:
- Cardinal Health upgraded to Outperform from In Line at Evercore ISI
- McKesson price target lowered to $650 from $680 at BofA
- Cardinal Health upgraded to Buy from Neutral at BofA
- Cardinal Health price target raised to $136 from $127 at Morgan Stanley
- Salesforce upgraded, ServiceNow downgraded: Wall Street’s top analyst calls